ACNÉ SEVERO PUBLICACIONES CIENTÍFICAS

01

Jul 2015

EFFECTIVENESS OF CONVENTIONAL, LOW-DOSE AND INTERMITTENT ORAL ISOTRETINOIN IN THE TREATMENT OF ACNE: A RANDOMIZED, CONTROLLED COMPARATIVE STUDY.

Lee JW1, Yoo KH, Park KY, Han TY, Li K, Seo SJ, Hong CKBr. J Dermatol. 2011 Jun;164(6):1369-75. doi: 10.1111/j.1365-2133.2010.10152.x. Epub 2011 May 17.

ABSTRACT

BACKGROUND:

The efficacy of conventional isotretinoin treatment (0·5-1·0 mg kg⁻¹daily for 16-32 weeks, reaching a cumulative dose of 120 mg kg⁻¹) for acne has been well established. To date, there are many reports regarding the efficacy of low-dose and intermittent isotretinoin treatment in patients with acne. Data comparing these three therapeutic regimens simultaneously, however, are unavailable.

OBJECTIVES:

To evaluate the clinical efficacy and tolerability of low-dose and intermittent isotretinoin regimens and tocompare them directly with conventional isotretinoin treatment.

METHODS:
In this study, 60 patients with moderate acne were enrolled and randomized to receive either isotretinoin at 0·5-0·7 mg kg⁻¹daily (group A), isotretinoin at 0·25-0·4 mg kg⁻¹daily (group B) or isotretinoin at 0·5-0·7 mg kg⁻¹daily for 1 week out of every 4 weeks (group C). The total period of drug administration was 6 weeks in group C, and 24 weeks in groups A and B. Evaluations included global acne grading system (GAGS) scores, lesion counts (inflammatory and noninflammatory), patient satisfaction and side-effects. A 1-year follow-up evaluation after the end of treatment was also performed.

RESULTS:

Differences in GAGS scores were statistically significant between groups A and C (P< 0·001) and groups B and C (P = 0·044). There was no significant difference between groups A and B. For the number of inflammatory lesions, there were statistically significant differences between groups B and C (P = 0·048) and groups C and A (P = 0·005). There was no significant difference between groups A and B. For the number of noninflammatory lesions, there were statistically significant differences between groups B and C (P = 0·046) and groups C and A (P=0·006). There was no significant difference between groups A and B. These results suggest that the conventional and low-dose regimens have similar efficacy. Intermittent treatment had less effect than either conventional or low-dose treatments. Patient satisfaction was highest in group B (3·76), followed by group C (3·31), then A (3·06), with statistically significant differences between groups A and B (P = 0·003) and groups B and C (P = 0·019) but no significant difference between groups A and C. This result suggests that the low-dose regimen is superior to other regimens (conventional or intermittent) in terms of patient satisfaction. Side-effects were more frequent with conventional treatment compared with low-dose and intermittent treatments. One year after the end of treatment, two of 16 patients relapsed in group A, three of 17 patients relapsed in group B, and nine of 16 patients relapsed in group C.

CONCLUSIONS:

Our study suggests that, when considering tolerability, efficacy and patient satisfaction, low-dose treatment is most suitable for patients with moderate acne.

doctor

COMENTARIOS

Dra. Ariadna Ortiz Brugués, Ph. D., dermatóloga y directora médica Pierre Fabre Dermocosmética

En este estudio se evalúa la eficacia de las dosis de isotretinoína oral convencionales (0.5 – 1mg/kg/d durante 16-32 semanas, dosis acumulada total 120mg/kg), frente a los usos intermintentes y las dosis bajas mantenidas.

Un total de 60 pacientes son randomizados en 3 grupos: 0.5-0.7 mg/kg/d durante 24 semanas (grupo A), 0.25-0.4mg/kg/d 24 semanas (grupo B) o 0.5-0.7 mg/kg/d durante la primera de cada 4 semanas, hasta un total de 6 semanas de ingesta de isotretinoína (grupo C). Como criterio de evaluación se emplea la global acne grading system.

En cuanto a los resultados, se objetiva que tanto las dosis convencionales (grupo A) como las bajas (grupo B) tienen una eficacia similar. El tratamiento intermitente (grupo C) fue menos efectivo. Además, el tratamiento a dosis bajas (grupo B) obtuvo un mayor grado de satisfacción por parte del paciente, y los efectos adversos fueron más frecuentes en el grupo que recibió las dosis convencionales frente al que recibió dosis bajas.

Los autores concluyen que las dosis bajas mantenidas son más eficaces en los casos de acné moderado.

“Los autores concluyen que las dosis bajas mantenidas son más eficaces en los casos de acné moderado.”

Juntos Contra el acné

Una iniciativa de Pierre Fabre Dermatologie una marca de Pierre Fabre Ibérica.